Investments made in the human insulin facility can support other products in Biocon’s research pipeline such as IN-105, the novel insulin conjugate for oral delivery and other insulin analogs. The expertise developed in protein processing, formulation and aseptic fill-finish is also leveraged for commercializing therapeutic peptides.